Skip to main
RXST

RxSight (RXST) Stock Forecast & Price Target

RxSight (RXST) Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 11%
Buy 0%
Hold 67%
Sell 22%
Strong Sell 0%

Bulls say

RxSight is expected to see a recovery in the second half of 2026, driven by an increase in utilization and a slight uptick in LDD placements. With an expected growth in low-single digit for LAL units, the overall growth should improve sequentially throughout the year. The company showed healthy gross margins in the fourth quarter of 2025, beating expectations due to a favorable product mix. However, investors should be aware of the risks, including limited adoption, potential competition, and the possibility of a dilutive financing round.

Bears say

RxSight is facing a number of risks that could limit adoption of its technology, such as the need for additional capital equipment, potential competition in the IOL market, and possible dilutive financing. The company also saw a decline in LDD placements and a slower-than-expected growth in LAL sales, which could indicate challenges in commercial execution. Additionally, the company's focus on driving LAL volumes through engagement initiatives may not be enough to offset flat to down LDD placements, which could lead to continued revenue declines. Overall, the company's uncertainty and slower-than-expected growth potential led to a negative outlook.

RxSight (RXST) has been analyzed by 9 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 22% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RxSight (RXST) Forecast

Analysts have given RxSight (RXST) a Hold based on their latest research and market trends.

According to 9 analysts, RxSight (RXST) has a Hold consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RxSight (RXST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.